Agios Pharmaceuticals | AGIO - Interest Expense On Debt


Agios Pharmaceuticals reported $1.18B in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amgen USD 657M 4M Mar/2026
Arrowhead Research USD 22.5M 811K Dec/2025
Astellas Pharma JPY 3.91B 320M Mar/2025
AstraZeneca USD 484M 181M Dec/2025
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Bristol-Myers Squibb USD 411M 21M Mar/2026
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Incyte USD 569K 13K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Merck USD 479M 67M Mar/2026
Moderna USD 11.49B 36B Mar/2026
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Novartis USD 343M 39M Mar/2026
Novartis USD 281M 8M Sep/2025
Pfizer USD 671M 40M Mar/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025